MONTREAL, Oct. 2, 2013 /CNW Telbec/ - The five Contenders of the first
AmorChem KNOCK-OUT Event valiantly climbed into the ring today at
BioContact to duke it out against a panel of Heavyweight Champions for
a chance to win a coveted $500,000 financing from AmorChem. Earlier
in the summer, AmorChem, the innovative Quebec-based venture capital
seed fund, launched a province-wide call for proposals to participate
in its KNOCK-OUT Event.
All the Contenders displayed remarkable courage and agility in the ring,
yet only one could stand victorious.
It is with great pleasure that AmorChem announces the winner of the 2013
Dr. John Stagg
"Targeting CD73 with small molecules in oncology"
Institut du cancer de Montréal, Centre de recherche du Centre
Hospitalier de l'Université de Montréal and Faculty of Pharmacy,
Université de Montréal
"This first KNOCK-OUT Event has been quite an adventure and we are very
pleased with the outcome of the battle in the ring today. The
Heavyweights had a tough job and we are very enthusiastic about their
selection," comments Inès Holzbaur, General Partner at AmorChem. "We
would like to thank the Contenders for rolling with the punches, our
Heavyweights for bringing their individual expertise into the ring
today and Christopher Hall for successfully keeping everyone battling
without the rule."
"Our hopes and objectives have been well surpassed for this Event," says
Elizabeth Douville, General Partner at AmorChem. "We created this Event
to increase the Quebec research community's awareness of AmorChem and
reach out to researchers who may not have been aware of the possibility
of commercialising aspects of their work. This Event definitely reached
The final bell has rung; AmorChem now looks forward to working with Dr
The AmorChem KNOCK OUT Event is proudly sponsored by ROBIC, LLP.
AmorChem L.P. (www.amorchem.com) is a venture capital fund located in Montreal focused on investing in
promising life science projects originating from Quebec-based
universities and research centres. The principal limited partners of
this fund are Investissement-Québec, FIER Partenaires, Fonds de
solidarité FTQ and Merck & Co. This fund is the latest addition to the
GeneChem portfolio of funds, a fund manager in existence since 1997.
AmorChem's innovative business model involves financing research-stage
projects to enable them to reach pre-clinical proof-of-concept ("POC")
in a semi-virtual mode within 18-24 months. The fund seeks to generate
returns through a two-pronged exit strategy: sell projects having
reached POC to large biotechnology or pharmaceutical companies; or
bundle them into new spin-out companies. AmorChem using external
resources will manage the projects. To that effect, AmorChem has
established a strategic partnership with the Biotechnology Research
Institute in order to access its R&D platforms. In addition, to
enabling projects requiring small molecules as tools or drug leads,
AmorChem has founded NuChem Therapeutics Inc., a medicinal chemistry
Founded in 1892, ROBIC, LLP is an internationally renowned firm of lawyers, patent and trade-mark
agents specialized in Intellectual Property and Business Law.
Headquartered in Montreal, ROBIC is a Canadian firm with more than 175
people including 23 partners and 45 professionals. We provide dynamic
and entrepreneurial assistance and representation to clients in
executing business transactions in addition to managing, protecting,
enforcing and commercialising their intellectual capital.
BioContact Quebec 2013: The 19th edition will take place on October 2nd and 3rd 2013, at the
Château Laurier in Québec City. Representatives from over 24
biopharmaceutical companies from Canada, the United States and Europe
will be attending.
For further information:
Media Contact for AmorChem
T 418 521 3771